CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION
Idiopathic pulmonary arterial hypertension (IPAH) is a rather rare cardiovascular disease of unknown origin and, at the same time, the most common form of pulmonary arterial hypertension (PAH). It is characterized by increased mean pulmonary artery pressure of ≥ 25 mm Hg and increased pulmonary vasc...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2019-12-01
|
| Series: | Евразийский Кардиологический Журнал |
| Subjects: | |
| Online Access: | https://www.heartj.asia/jour/article/view/347 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849402547702333440 |
|---|---|
| author | Z. S. Valieva T. V. Martynyuk |
| author_facet | Z. S. Valieva T. V. Martynyuk |
| author_sort | Z. S. Valieva |
| collection | DOAJ |
| description | Idiopathic pulmonary arterial hypertension (IPAH) is a rather rare cardiovascular disease of unknown origin and, at the same time, the most common form of pulmonary arterial hypertension (PAH). It is characterized by increased mean pulmonary artery pressure of ≥ 25 mm Hg and increased pulmonary vascular resistance of > 3 Wood units. One of the key components of IPH pathogenesis is the disorder in the prostacyclin pathway leading to hypertrophy of the smooth muscle and endothelial cells, fibrotic changes, inflammatory response and vasoconstriction, which results in small artery and arteriole remodeling. For severe cases of PAH, in Russia only used one drug acting on the prostacyclin pathway, i.e., iloprost for inhalation. However, this therapy has a number of restrictions on the use. Selexipag is the first selective oral prostacyclin IP-receptor agonist intended for the treatment of patients with PAH. The efficacy and safety of Selexipag in patients with PAH were investigated in GRIPHON study, the largest-scale clinical trial ever conducted in patients with pulmonary hypertension. The publication presents a case of successful use of Selexipag as a part of the combination therapy in a patient with IPAH. |
| format | Article |
| id | doaj-art-5209084e7a3e4f1fbb77214a0a3abcce |
| institution | Kabale University |
| issn | 2225-1685 2305-0748 |
| language | Russian |
| publishDate | 2019-12-01 |
| publisher | InterMedservice |
| record_format | Article |
| series | Евразийский Кардиологический Журнал |
| spelling | doaj-art-5209084e7a3e4f1fbb77214a0a3abcce2025-08-20T03:37:31ZrusInterMedserviceЕвразийский Кардиологический Журнал2225-16852305-07482019-12-010414415510.38109/2225-1685-2019-4-144-155346CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSIONZ. S. Valieva0T. V. Martynyuk1Institute named after A.L. MyasnikovInstitute named after A.L. MyasnikovIdiopathic pulmonary arterial hypertension (IPAH) is a rather rare cardiovascular disease of unknown origin and, at the same time, the most common form of pulmonary arterial hypertension (PAH). It is characterized by increased mean pulmonary artery pressure of ≥ 25 mm Hg and increased pulmonary vascular resistance of > 3 Wood units. One of the key components of IPH pathogenesis is the disorder in the prostacyclin pathway leading to hypertrophy of the smooth muscle and endothelial cells, fibrotic changes, inflammatory response and vasoconstriction, which results in small artery and arteriole remodeling. For severe cases of PAH, in Russia only used one drug acting on the prostacyclin pathway, i.e., iloprost for inhalation. However, this therapy has a number of restrictions on the use. Selexipag is the first selective oral prostacyclin IP-receptor agonist intended for the treatment of patients with PAH. The efficacy and safety of Selexipag in patients with PAH were investigated in GRIPHON study, the largest-scale clinical trial ever conducted in patients with pulmonary hypertension. The publication presents a case of successful use of Selexipag as a part of the combination therapy in a patient with IPAH.https://www.heartj.asia/jour/article/view/347diopathic pulmonary arterial hypertensionpulmonary arterial hypertensionselexipag |
| spellingShingle | Z. S. Valieva T. V. Martynyuk CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION Евразийский Кардиологический Журнал diopathic pulmonary arterial hypertension pulmonary arterial hypertension selexipag |
| title | CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION |
| title_full | CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION |
| title_fullStr | CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION |
| title_full_unstemmed | CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION |
| title_short | CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION |
| title_sort | case report on the successful use of a new selective prostacyclin ip receptor agonist selexipag in a patient with idiopathic pulmonary hypertension |
| topic | diopathic pulmonary arterial hypertension pulmonary arterial hypertension selexipag |
| url | https://www.heartj.asia/jour/article/view/347 |
| work_keys_str_mv | AT zsvalieva casereportonthesuccessfuluseofanewselectiveprostacyclinipreceptoragonistselexipaginapatientwithidiopathicpulmonaryhypertension AT tvmartynyuk casereportonthesuccessfuluseofanewselectiveprostacyclinipreceptoragonistselexipaginapatientwithidiopathicpulmonaryhypertension |